Professor, Medicine, University of Miami School of Medicine
Infectious Disease
Dr. Dushyantha T. Jayaweera, MD
|
|
Give Review
Dushyantha Jayaweera practices Infectious Disease. Dushyantha Jayaweera is a published doctor. He has 47 publications published. The most current publication "[Cytomegalovirus polyradiculomyelopathy in AIDS]." He accepts all Medicare patients.
Publications
- New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data.
- Quality of life, symptomatology and healthcare utilization in HIV/HCV co-infected drug users in Miami.
- Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients.
- Effect of class-specific therapy interruption on persistence of HIV type 1 antiretroviral resistance.
- Differences in the frequency of resistance to antiretroviral drug classes among human immunodeficiency virus type 1 clinical isolates.
- Wernicke''s encephalopathy in AIDS: a preventable cause of fatal neurological deficit.
- Field evaluation of the Determine rapid human immunodeficiency virus diagnostic test in Honduras and the Dominican Republic.
- Pre-treatment with hydration and electrolytes may prevent dose limiting toxicities during foscarnet induction therapy.
- Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study.
- Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2.
- Would switching the protease inhibitors (PI) to tenoforvir be an option in controlling hypertriglyceridaemia secondary to PIs? A case report.
- Effectiveness and tolerability of a once-daily amprenavir/ritonavir-containing highly active antiretroviral therapy regimen in antiretroviral-naïve patients at risk fo...
- Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrom...
- The safety and efficacy of indinavir and ritonavir (400/400 mg BID) in HIV-1-infected individuals from an inner-city minority population: a pilot study.
- MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates.
- C-reactive protein: a poor marker of cardiovascular disease risk in HIV+ populations with a high prevalence of elevated serum transaminases.
- [Cytomegalovirus polyradiculomyelopathy in AIDS].
- Hepatitis B markers in heterosexual patients attending two genitourinary medicine clinics in the West Midlands.
- Minimising the dosage-limiting toxicities of foscarnet induction therapy.
- Pediculosis pubis: a surrogate marker for sexually transmitted diseases.
- Toxoplasma seroprevalence in HIV-positive patients in West Midlands.
- Genital warts and the need for screening.
- Laboratory techniques for the diagnosis of chlamydia infections.
- Extrapyramidal manifestations in cerebral malaria.
- Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS.
- Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovirus infections.
- Fulminant neuropathy and lactic acidosis associated with nucleoside analog therapy.
- Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.
- Coinfection with hepatitis C virus, oxidative stress and antioxidant status in HIV-positive drug users in Miami.
- Gender differences in medication management capacity in HIV infection: the role of health literacy and numeracy.
- Virologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimen in treatment-Naïve HIV-1-infected patients over 96 weeks.
- Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.
- Human immunodeficiency virus type 1 pharmacogenomics in clinical practice: relevance of HIV-1 drug resistance testing (Part 1).
- Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression.
- Outcomes after orthotopic liver transplantation in 15 HIV-infected patients.
- Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from ...
- Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
- Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
- Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults.
- Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease.
- Genotypic analysis of plasma HIV-1 RNA after influenza vaccination of patients with previously undetectable viral loads.
- Human immunodeficiency virus type 1 pharmacogenomics in clinical practice: relevance of HIV-1 drug resistance testing (Part 2).
- A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.
- Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients.
- Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial.
- Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors.
Schools
University Of Colombo
Edward Hines Jr Va Hospital
Doctors Specialties
- Internal Medicine
- Infectious Disease
Accepted Insurances
Hospital
-
University of Miami Hospital
Drug Facts
| NPI NUMBER | 1548224405 | |
| NPPES Provider LastName | JAYAWEERA | |
| NPPES Provider FirstName | DUSHYANTHA | |
| NPPES Provider ZIPCode | 331361005 | |
| NPPES Provider State | FL | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 3866.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 31.0 | |
| Percent Opioid Claims | 0.8 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1548224405 |
| Last Name Of The Provider | JAYAWEERA |
| First Name Of The Provider | DUSHYANTHA |
| View All |
Similar Doctors
|
Dr. Rosa M. Garcia, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Raiza Perez, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jorge B. Mordujovich, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Rafael Crespo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carmen Z. Andux, MD |
|
|
Dr. Mercedes J. Pino, MD |
|
|
Dr. Manuel R. Cotilla, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert J. Hernandez, MD
This Doctor is OpenDoctor Recommended.
|